Fellows of the British Pharmacological Society are members who have demonstrated distinction and peer recognition in pharmacology.
Fellows have made, and may continue to make, substantial contributions to the disciplines of pharmacology, clinical pharmacology and therapeutics, through their work, publication and presentation of research, leadership, and contribution to Society life.
Find out more and apply for Fellowship.
This directory has been created to increase the visibility of our Fellows and their contributions, and to support networking by providing a useful resource for members to connect with Fellows with similar areas of interest.
Here you can find profiles of each Fellow, including information on their institutional affiliation, year elected, primary professional setting, affinity group membership, and a short biography.
Select the magnifying glass icon to begin any searches.
Dr Adcock graduated in 1987 from the University of London with a PhD in Molecular Pharmacology investigating the role of steroid hormones on brain sexual dimorphism.
Specialising in and with a recognised expertise in sensory neurophysiology and neuropharmacology, particularly in airway disease (including airway hyperresponsiveness, asthma, COPD and chronic cough).
Elizabeth Adeyeye is a specialist registrar in Clinical Pharmacology and Therapeutics and General Internal Medicine at University College London Hospitals NHS Trust.
Nika Adham, MSc,PhD FBPhS, Executive Director of Biological Research, External Science and Innovation at Allergan.
I received my PharmD from Tehran University of Medical Sciences (TUMS) in 1989.
Ana Alfirevic is Professor Em of Pharmacology and Personalised Medicine at the University of Liverpool.
Provides clinical pharmacology expertise required for the delivery of early phase studies in clinical drug development to the pharmaceutical industry.
Ruth Andrew is a pharmacist whose research has dissected the roles of glucocorticoid hormones in metabolic disease.
Stephen Ankier completed a PhD in pharmacology at the School of Pharmacy in London (1967) and then joined Allen & Hanbury’s where he directed a preclinical unit to evaluate novel compounds in the search for new medicines.
Daniel Anthony is Professor of Experimental Neuropathology in the Department of Pharmacology at the University of Oxford where he explores the contribution of inflammation to CNS injury and disease.